Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease

Purpose Sodium-glucose cotransporter 2 (SGLT2) inhibitors have important cardiovascular and renal benefits in adults with type 2 diabetes who have or are at high risk of cardiovascular and renal disease. These benefits are seen in patients with impaired renal function where the glucose-lowering effe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 2019-11, Vol.75 (11), p.1481-1490
Hauptverfasser:	Milder, Tamara Y., Stocker, Sophie L., Samocha-Bonet, Dorit, Day, Richard O., Greenfield, Jerry R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedical and Life Sciences Biomedicine Cardiovascular diseases Cardiovascular Diseases - prevention & control Clinical trials Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Glucose Glucose - metabolism Health risks Humans Inhibitors Kidney - drug effects Kidney - metabolism Kidney diseases Kidneys Pharmacokinetics Pharmacology Pharmacology/Toxicology Renal function Renal Insufficiency, Chronic - drug therapy Renal Insufficiency, Chronic - metabolism Review Sodium Sodium-glucose cotransporter Sodium-Glucose Transporter 2 Inhibitors - pharmacokinetics Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!